Core Viewpoint - The stock of Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase, rising nearly 7% before stabilizing at a 5.82% gain, trading at HKD 15.08 with a transaction volume of HKD 73.088 million [1] Group 1: Clinical Research Developments - The company announced early clinical research results for three cell cycle protein-dependent kinase inhibitors (CDKis): TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which will be presented at the 2025 ESMO Annual Meeting in Berlin from October 17 to 21 [1] - Tongyuan Kang's drug, Aditinib (TY-9591), targeting non-small cell lung cancer brain metastases, has garnered significant attention following its key Phase II clinical trial results presented at the World Lung Cancer Conference in September 2025 [1] Group 2: Regulatory Milestones - The company completed the enrollment of 224 patients for the conditional approval of Aditinib in November 2024 and submitted a Pre-NDA application in April 2025, with plans to formally submit a conditional NDA application in Q4 2025 [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 3%, currently trading at 15.53 HKD with a transaction volume of 5.21 million HKD, following the announcement of early clinical research results for three CDK inhibitors [1] Group 1: Company Developments - On October 21, Tongyuan Kang Pharmaceutical-B announced that its board is pleased to present early clinical research results for three key drugs in the CDK inhibitor field: TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the European Society for Medical Oncology (ESMO) annual meeting, which is one of the most influential academic events in the oncology field [1] Group 2: Industry Context - The ESMO 2025 annual meeting is scheduled to take place from October 17-21, 2025, in Berlin, Germany, attracting top experts and scholars to discuss clinical challenges and share cutting-edge advancements [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has announced early clinical research results for three drugs in the cell cycle protein-dependent kinase inhibitor (CDKi) field, which were presented at the European Society for Medical Oncology (ESMO) annual meeting [1] Group 1: Company Performance - The stock price of Tongyuan Kang Pharmaceutical-B increased by over 3% at the beginning of trading and is currently up by 1.52%, trading at 15.40 HKD with a transaction volume of 18.24 million HKD [1] Group 2: Clinical Research and Events - The three drugs highlighted are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i), which are part of the company's strategic focus [1] - The ESMO 2025 annual meeting will take place from October 17-21, 2025, in Berlin, Germany, and is recognized as one of the most influential academic events in the oncology field, attracting top experts and scholars [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 3%, currently trading at 15.53 HKD with a transaction volume of 5.21 million HKD, following the announcement of early clinical research results for three CDK inhibitors at the ESMO 2025 conference [1] Company Summary - On October 21, Tongyuan Kang Pharmaceutical-B announced that its board is pleased to present early clinical research results for three key drugs in the cyclin-dependent kinase inhibitor (CDKi) field: TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the European Society for Medical Oncology (ESMO) 2025 conference, which is scheduled to take place from October 17-21, 2025, in Berlin, Germany [1] - ESMO is recognized as one of the most influential academic events in the oncology field, attracting top experts and providing a platform for discussing clinical challenges and sharing cutting-edge advancements [1]

Core Insights - The company Tongyuan Kang Pharmaceutical-B (02410.HK) announced early clinical research results for three drugs in the cyclin-dependent kinase (CDK) inhibitor field, specifically TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] Group 1: Clinical Research - The early clinical research results were presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting [1] - The ESMO 2025 annual meeting took place from October 17-21, 2025, in Berlin, Germany [1] - ESMO is recognized as one of the most influential academic events in the oncology field, attracting top experts and scholars [1]

Core Insights - Company announced early clinical research results for three drugs in the cell cycle protein-dependent kinase inhibitor (CDKi) field, namely TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - Results were presented in poster format at the European Society for Medical Oncology (ESMO) annual meeting, a significant event in the oncology field [1] Company Developments - The company is focusing on the development of CDKi drugs, indicating a strategic emphasis on this therapeutic area [1] - The ESMO 2025 annual meeting will take place from October 17-21, 2025, in Berlin, Germany, highlighting the company's engagement with leading experts in oncology [1]

Core Viewpoint - The company announced early clinical research results for three cell cycle protein-dependent kinase inhibitors (CDKis) at the European Society for Medical Oncology (ESMO) annual meeting, highlighting its strategic focus in this area [1] Group 1: Clinical Research - The three CDK inhibitors presented are TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the ESMO 2025 annual meeting, which is a significant event in the oncology field [1] Group 2: Event Details - The ESMO 2025 annual meeting is scheduled to take place from October 17-21, 2025, in Berlin, Germany [1] - This meeting is recognized as one of the most influential academic gatherings in oncology, attracting top experts and scholars [1]

本公告乃由浙江同源康醫藥股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資 料。 本公司董事（「董事」）會（「董事會」）欣然宣佈重點佈局的細胞周期蛋白依賴性激 酶（「CDK」）抑制劑(CDKi)領域的三款藥物TYK-00540 (CDK2/4i)、TY-2699a (CDK7i)和TY-302 (CDK4/6i)的早期臨床研究結果以壁報形式在歐洲腫瘤內科學 會（「ESMO」）年會上展示。 ESMO 2025年會於當地時間2025年10月17-21日在德國柏林召開。作為全球腫瘤 學領域最具影響力的學術盛會之一，ESMO年會吸引了眾多學界頂尖專家學者， 提供了共同探討臨床難題、分享前沿進展的舞台。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願性公 ...

Core Viewpoint - The company, Tongyuan Kangyi Yao-B (02410), has proposed to adopt the 2025 H-share incentive plan, indicating a strategic move to enhance employee motivation and align their interests with shareholders [1] Group 1 - The board of directors has recommended the implementation of the 2025 H-share incentive plan [1]

Core Viewpoint - The company proposes amendments to its articles of association to innovate its organizational structure and enhance the protection of minority shareholders' rights, while also abolishing the supervisory board and assigning its functions to the audit committee of the board of directors, effective from July 1, 2024, in accordance with the revised Company Law of the People's Republic of China [1] Group 1 - The company aims to reform its organizational structure [1] - The amendments are intended to strengthen the protection of minority shareholders' rights [1] - The supervisory board will be abolished, with its powers transferred to the audit committee [1]